



FOR COMPREHENSIVE DIABETES CARE

Linahenz-5

Linagliptin 5 mg Tablets

Linahenz-M 500

Linagliptin 2.5 mg + Metformin 500 mg Tablets

Linahenz-M 1000

Linagliptin 2.5 mg + Metformin 1000 mg Tablets

Linahenz-M OD 500

Linagliptin 5 mg + Metformin (ER) 500 mg Tablets

Linahenz-M OD 1000

Linagliptin 5 mg + Metformin (ER) 1000 mg Tablets

La Renon

Linahenz-5

Linagliptin 5 mg Tablets

Linahenz-M 500

Linagliptin 2.5 mg + Metformin 500 mg Tablets

Linahenz-M 1000

Linagliptin 2.5 mg + Metformin 1000 mg Tablets

Linahenz-M OD 500

Linagliptin 5 mg + Metformin (ER) 500 mg Tablets

Linahenz-M OD 1000

Linagliptin 5 mg + Metformin (ER) 1000 mg Tablets

Background

Many currently available combinations for patients with Type-2 diabetes mellitus are associated with hypoglycaemia and/or weight gain which act as barriers to the achievement of glycemic and weight control. Linagliptin a new DPP-4 inhibitor offers another option for the treatment of inadequately controlled T2DM in patients who are already receiving metformin or Sulfonylurea. As per American Diabetes Association, metformin is the first drug of choice for T2DM. The patients who do not respond to metformin monotherapy alone may require combination therapy. The metformin when combined with DPP-4 inhibitor promotes glucose lowering effect which is weight neutral with low intrinsic risk of hypoglycaemia having a complementary mechanism. Thus, metformin and Linagliptin combination could be a rational step to achieve control of blood glucose level.

Indication

LINAHENZ / LINAHENZ-M / LINAHENZ-M OD : Indicated as an adjunct to diet & exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Mechanism of Action

- **Linagliptin** selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 & glucose-dependent insulinotropic peptide to facilitate glucose regulation in response to a meal.
- **Metformin** decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose & increasing insulin sensitivity by increasing peripheral glucose uptake & utilization.

Key Features of Linagliptin

- No dose adjustment is required for patients with renal impairment.
- Reduces albuminuria burden and HbA1c, without affecting CV or kidney risk.
- Improves Renal Function.
- Shows long-term CV & kidney safety profile

Dosage & Administration

- **Linahenz-5** : The recommended dose is once daily orally or as prescribed by the physician.
- **Linahenz-M** : The recommended dose is 1-2 tablet a day orally or as prescribed by the physician.
- **Linahenz-M OD** : The recommended dose is once daily orally or as prescribed by the physician.



Scan for more
Prescribing Information

References : 1. J Clin Endocrinol Metab. 2013 Jul;98(7):E1163-72. | 2. Circulation. 2019;139:351-361. | 3. Drugs (2014) 74:1927-1946 | 4. P T.2011 Dec; 36(12): 807-812, 842. | 5. Diabet Med. 2011 Nov;28(11):1352-61

La Renon Healthcare Private Limited

207 - 208 Iscon Elegance | Circle P | Prahlad Nagar Cross Roads | S.G. Highway
Ahmedabad - 380015 | Gujarat | India. | Phone : + 91-79-6616-8998 | 2693-6656
Fax : +91-79-6616-8998 | E-mail : info@larenon.com | Web : www.larenon.com

©2024 All rights reserved, La Renon Healthcare Private Limited

